Influenza season, vaccine innovation, and H5 preparedness

WHO is gathering surveillance and vaccine-response evidence for the 2027 Southern Hemisphere influenza vaccine composition, including zoonotic A(H5) threats. A reported mRNA flu-vaccine approval for U.S. adults aged 50 and older, Delhi's 2,308 confirmed H1N1 cases, and preclinical evidence that lung immune cells may improve nasal-vaccine responses are notable, but comparative effectiveness and human translation remain unresolved.